The Antibody That Half the Market Rents

There is a biomarker in your blood that correlates with the brain pathology of Alzheimer’s disease — and researchers can now estimate, from its concentration, the likely window before cognitive symptoms appear. It is called p-Tau217, and it is one of the most extensively validated blood-based biomarkers for Alzheimer’s disease. A plasma sample, run on an automated immunoassay analyser, can tell a clinician whether the underlying pathology is present with a degree of confidence that, two years ago, required a lumbar puncture or a PET scan.

The previous essay argued that routine chemistry has converged into an engineering commodity and that the real differentiation has moved to the specialised immunoassay niches. Alzheimer’s diagnostics is the clearest illustration of that thesis in a decade. And it has produced something I did not anticipate: a structural map of who is ready for the next category — and who is not.

Five houses on the same avenue. Three built their own foundations — slower, but the ground is theirs. Two rented the same building material from the same quarry, and entered the market faster. And there is a sixth group: the houses that have no construction on this street at all.

The assay everyone is watching

p-Tau217 is phosphorylated tau at threonine 217. It reflects the accumulation of amyloid and tau in the brain — the two hallmarks of Alzheimer’s — and does so from plasma, not cerebrospinal fluid. In the last two years, studies in Nature Medicine demonstrated that population-level p-Tau217 trajectories can estimate the likely timing of symptom onset within a few years. Head-to-head comparisons have shown that plasma p-Tau217 assays, for amyloid and tau pathology classification, approach the diagnostic accuracy of cerebrospinal fluid — though the comparison depends on the assay, the platform, and the specific biomarker being measured.

This is not a promising early-stage biomarker awaiting validation. It is a peer-reviewed, published biomarker with regulatory clearances already accumulating, and it is changing the conversation about how Alzheimer’s is diagnosed.

That conversation used to live in the neurologist’s office — PET imaging, cognitive assessment, spinal fluid. p-Tau217 moves part of it to the clinical laboratory. Not the same floor as your thyroid hormones, exactly; p-Tau217 requires assay development specific to each immunoassay platform, with dedicated calibrators, reference intervals, and regulatory clearance. But the direction of travel is clear: from the specialist imaging suite toward the automated laboratory, one validation study at a time.

Three strategies, one molecule

Here is where the structural detail matters. Five diagnostics platforms are competing in this space, and they chose three different paths.

Two of them developed their own antibodies in-house — years of R&D, clinical evidence, and regulatory work, but full control of their intellectual property. A third manufacturer, headquartered in Asia, took the same independent route: its own antibody, its own assay architecture, its own regulatory dossier. That makes three platforms built on proprietary capture molecules.

The other two took a different path: they licensed the same monoclonal antibody from the same small biotechnology company. A private biotech — the kind that does not manufacture kits, does not operate a laboratory, does not sell to hospitals — developed an antibody against p-Tau217 that became, through a combination of scientific merit and timing, the capture molecule two of the five giants chose to build their Alzheimer’s assay around. In the span of eighteen months, two global licensing agreements were signed.

I will not name the companies, because the point is structural, not commercial. What matters is the pattern: of five platforms entering the most consequential new category of specialised immunoassay in a decade, two depend on a third party for their most critical biological input. The other three do not.

Licensing an externally developed antibody is faster than building one in-house — the licensing company gets a validated molecule with published evidence, and the biotech gets royalties and relevance. In a race where speed-to-market matters, the logic is sound. But it creates something that does not appear on a specification sheet: a concentration of dependency.

What happens when two giants share the same ingredient

I want to be precise about what this dependency means and what it does not mean. Two companies licensing the same antibody do not produce identical assays. Each develops its own calibrators, its own signal-detection chemistry, its own assay architecture, and its own regulatory dossier. The final product is a distinct immunoassay that happens to share a critical input. Anyone who has run method comparisons knows that the capture antibody is one variable among many in the performance of an immunoassay — but it is not a trivial variable.

The dependency risk is not that both assays will suddenly stop working. A well-negotiated licensing agreement will contain supply guarantees, change-of-control provisions, and manufacturing rights that protect the licensee. The legal departments of the companies involved are not naive. But there is a structural asymmetry that a specification sheet cannot capture: two of the five platforms depend on a third party for the most critical biological input in their newest specialised assay, and the other three do not. If the licensing company is acquired, if the antibody’s IP is contested, or if the supply relationship deteriorates, the licensing giants face a renegotiation their in-house competitors never will.

The specification sheet tells you the assay works. It does not tell you that your vendor rents the molecule that makes it work.

The houses that aren’t on the avenue yet

There is a third group that the specification sheets do not mention at all, because it has no specification sheet for p-Tau217. I am talking about the manufacturers — several of them dominant in routine chemistry and basic immunoassay across Latin America — who have not entered this category.

These are companies that compete aggressively on throughput, menu size, and price per test. Their analysers run thyroid hormones, metabolic panels, routine infectious disease serology. Some of them have built strong positions in the Mexican market by offering platforms that are, on the floor of routine work, entirely capable. But none of them has a p-Tau217 assay. None has announced one. None has, as far as public regulatory filings show, licensed the antibody or published validation data.

This is not a failure. It is a signal. The same essay that predicted the convergence of routine chemistry also predicted that the specialised floor would become the real battleground. A manufacturer without a specialised immunoassay strategy for Alzheimer’s is not behind on one test — they are absent from the category that is redrawing the map of where differentiation lives. And the longer they remain absent, the harder the entry becomes: the platforms that moved first are already accumulating clinical evidence, building reference accounts, and negotiating regulatory pathways in the markets that will set the standard.

When COFEPRIS opens its window for blood-based Alzheimer’s diagnostics — and it will, though the window is more likely measured in years than months — the laboratories that positioned themselves early will have built clinical reference while others were still evaluating the regulatory landscape. Those that wait for the category to commoditise may find that the manufacturers who moved first have already captured the reference accounts. And the manufacturers who never entered at all will have handed that opportunity to their competitors.

The question that should be in every tender

When I wrote about the seven readings for evaluating a vendor, the framework assumed that the vendor controls the technology behind the assay. In the case of licensed biomarkers, that assumption deserves a closer look. There is a question worth asking of any specialised assay where a critical antibody or reagent comes from a third party: who owns the molecule, and what does that mean for supply continuity over the life of this contract?

This is not a reason to avoid platforms that license externally. Licensing is a legitimate, sometimes superior strategy — it can bring better-validated assays to market faster than in-house development. And in-house development carries its own risks: cell lines lose productivity, key scientists leave, manufacturing facilities fail. No antibody supply chain is risk-free. The point is that the shape of the risk is different, and a buyer who understands the shape makes a more durable decision.

There is a second question, and it is newer: does my vendor have a strategy for this category at all? A manufacturer without a p-Tau217 assay today is not necessarily disqualified — the category is young, and entry is still possible. But a laboratory that builds its specialised menu around a vendor with no apparent intention of entering Alzheimer’s diagnostics is making a long-term bet on a platform that may not follow them into the next decade of specialised testing.

Why this matters more in our market than in Boston

In markets with mature reimbursement systems, the Alzheimer’s blood-testing pipeline is advancing through regulatory clearance and payer coverage at speed. By the time these assays become standard of care in the United States or Western Europe, the dependency question will have been resolved one way or another.

In Latin America, the timeline is longer. The regulatory framework for blood-based Alzheimer’s diagnostics does not exist in most countries of the region. COFEPRIS, ANVISA, INVIMA — none has an established pathway for this category yet. When it arrives, the laboratories that have positioned themselves early will have built clinical reference while others were still evaluating the regulatory landscape. Those that wait for the category to commoditise may find that the manufacturers who moved first have already captured the reference accounts.

The buyer who understands the structural landscape — who built their own antibody, who licensed it, and what that means for supply continuity — will make a more informed decision. The buyer who treats the assay as a line item on a menu may discover, years into a contract, that the question they should have asked was never on the specification sheet.

The antibody that half the market rents is not a catastrophe. It is a signal. It tells you that in the most consequential new category of specialised immunoassay in a decade, the ownership of the molecule matters — alongside, not instead of, the performance of the platform. And the silence from the houses that have not entered the avenue tells you something else: that the race on the specialised floor has already started, and not everyone has shown up to run.

In a market where contracts lock you in for five years and switching costs are measured in revalidation studies, that signal is worth more than any throughput number on a brochure.